Shunjun Fu
Impact in
- Hepatology top 2%
- Hepatocellular Carcinoma Treatment and Prognosis
- Oncology top 5%
- Inflammatory Biomarkers in Disease Prognosis
- Cancer Immunotherapy and Biomarkers
- Pancreatic and Hepatic Oncology Research
Papers in
- Hepatology 14
- Hepatocellular Carcinoma Treatment and Prognosis 13
- Oncology 13
- Inflammatory Biomarkers in Disease Prognosis 7
- Pancreatic and Hepatic Oncology Research 3
- Cancer Immunotherapy and Biomarkers 2
- Co-authors
- Baogang Peng (16 shared papers)Shaoqiang Li (15 shared papers)Li‐Jian Liang (7 shared papers)Yunpeng Hua (11 shared papers)Weikai Xiao (5 shared papers)Beichu Guo (3 shared papers)Jinyu Zhang (1 shared paper)Bei Liu (1 shared paper)
- Journals
- BMC Cancer (6 papers)Journal of Visualized Experiments (3 papers)Scientific Reports (2 papers)Oncotarget (2 papers)Anti-Cancer Agents in Medicinal Chemistry (2 papers)
- Partner nations
- ChinaUnited StatesHong Kong
In The Last Decade
Shunjun Fu
45 papers receiving 1.3k citations
Peers
Comparison fields: 5 of 86
- Hepatology 272
- Oncology 532
- Cancer Research 226
- Immunology 204
- Epidemiology 156
Countries citing papers authored by Shunjun Fu
This map shows the geographic impact of Shunjun Fu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shunjun Fu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shunjun Fu more than expected).
Fields of papers citing papers by Shunjun Fu
This network shows the impact of papers produced by Shunjun Fu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shunjun Fu. The network helps show where Shunjun Fu may publish in the future.
Co-authors
The 25 scholars most cited alongside Shunjun Fu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 49 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2016 | 239 | |
| 2 | 2014 | 191 | |
| 3 | 2016 | 95 | |
| 4 | 2014 | 86 | |
| 5 | 2013 | 74 | |
| 6 | 2015 | 60 | |
| 7 | 2017 | 48 | |
| 8 | 2013 | 45 | |
| 9 | 2016 | 43 | |
| 10 | 2014 | 41 | |
| 11 | 2015 | 41 | |
| 12 | 2014 | 31 | |
| 13 | 2016 | 29 | |
| 14 | 2015 | 25 | |
| 15 | 2020 | 22 | |
| 16 | 2018 | 22 | |
| 17 | 2017 | 19 | |
| 18 | GPC3 DNA vaccine elicits potent cellular antitumor immunity against HCC in mice. | 2014 | 16 |
| 19 | 2023 | 14 | |
| 20 | 2022 | 13 |
About Shunjun Fu
Shunjun Fu is a scholar working on Hepatology, Oncology, Cancer Research, Molecular Biology and Surgery, having authored 49 papers that have together received 1.3k indexed citations. Recurring topics across this work include Hepatocellular Carcinoma Treatment and Prognosis (13 papers), Inflammatory Biomarkers in Disease Prognosis (7 papers), MicroRNA in disease regulation (5 papers), Liver Disease Diagnosis and Treatment (4 papers), Circular RNAs in diseases (4 papers), Pancreatic and Hepatic Oncology Research (3 papers), Ferroptosis and cancer prognosis (2 papers) and Cancer Immunotherapy and Biomarkers (2 papers). The work is most often cited by research in Hepatology (272 citations), Oncology (532 citations), Cancer Research (226 citations), Immunology (204 citations) and Epidemiology (156 citations). Shunjun Fu has collaborated with scholars based in China, United States and Hong Kong. Frequent co-authors include Baogang Peng, Shaoqiang Li, Li‐Jian Liang, Yunpeng Hua, Weikai Xiao, Beichu Guo, Jinyu Zhang, Bei Liu, Zihai Li and Shunli Shen. Their work appears in journals such as BMC Cancer, Journal of Visualized Experiments, Scientific Reports, Oncotarget and Anti-Cancer Agents in Medicinal Chemistry.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.